Summary: Tonix Pharmaceuticals presented new data at the American College of Rheumatology’s 2024 meeting, demonstrating that its drug candidate TNX-102 SL significantly reduces pain and improves sleep quality in fibromyalgia patients. In the phase 3 RESILIENT study, the drug met … [Read more...]
Sublingual Treatment Aids Sleep and Reduces PTSD in Veterans
A phase 3 study found that bedtime sublingual cyclobenzaprine (TNX-102 SL), an investigational drug being developed by Tonix Pharmaceuticals Holding Corp, is well-tolerated and showed nominal improvement in post-traumatic stress disorder (PTSD) severity and sleep quality measures … [Read more...]